Skip to main content
Premium Trial:

Request an Annual Quote

Gyros Pockets $6M More for Series B Round

NEW YORK, April 11 - Swedish mass-spec company Gyros today said it has closed an additional $6 million in its second private-equity round of financing, bringing to $36 million the total second-round booty.


Gyros recently unveiled its Gyrolab MALDI SP1 and Gyrolab Workstation, both of which will be shown off at a number of meetings in the US and Europe in the coming months.


In January, Gyros said it and ACE BioSciences plan to test its new technique for miniaturizing and automating sample preparation for protein identification.


The Gyros system is designed to automate sample prep for MALDI mass spectrometry and boost sensitivity in protein identification. It is a new application of the company's core platform, by which laboratory processes are miniaturized and embedded into CDs for parallel preparation and processing.


Gyros, based in Uppsala, was spun off from Amersham Pharmacia Biotech in 2000.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.